📣 VC round data is live. Check it out!

Curiox Biosystems Valuation Multiples

Discover revenue and EBITDA valuation multiples for Curiox Biosystems and similar public comparables like Conmed, Mani Inc., Kuros Biosciences, Integra Lifesciences and more.

Curiox Biosystems Overview

About Curiox Biosystems

Curiox Biosystems Co Ltd is Korean Based company which brings together decades of scientific and engineering expertise in surface chemistry and life science instrumentation with the goal of overcoming critical challenges that slow the pace of life science research. The company has introduced Laminar Wash technology, which automates cell processing and enables highly reproducible and high-throughput cell analysis. The company offers various products such as LAMINAR WASH AUTO 1000 SYSTEM, Curiox Laminar Wash HT2000 System and Laminar Wash MINI System.


Founded

2018

HQ

South Korea

Employees

N/A

Financials (LTM)

Revenue: $3M
Net Income: ($18M)

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Curiox Biosystems Financials

Curiox Biosystems reported last 12-month revenue of $3M.

In the same LTM period, Curiox Biosystems generated had net loss of ($18M).

Revenue (LTM)


Curiox Biosystems P&L

In the most recent fiscal year, Curiox Biosystems reported revenue of $3M and EBITDA of ($16M).

Curiox Biosystems is unprofitable as of last fiscal year, with gross margin of 41%, EBITDA margin of (452%), and net margin of (520%).

See analyst estimates for Curiox Biosystems
LTMLast FY202320242025202620272028
Revenue$3M$3M$5M$3M$3M
Gross Profit$1M$3M$2M$1M
Gross Margin41%56%56%41%
EBITDA($16M)($6M)($3M)($16M)
EBITDA Margin(452%)(121%)(103%)(452%)
EBIT Margin(237%)(235%)(156%)(292%)(239%)
Net Profit($18M)($18M)($7M)($5M)($18M)
Net Margin(523%)(520%)(148%)(176%)(528%)

Financial data powered by Morningstar, Inc.

Curiox Biosystems Stock Performance

Curiox Biosystems has current market cap of $1B, and enterprise value of $1B.

Market Cap Evolution


Curiox Biosystems' stock price is $61.81.

Curiox Biosystems share price decreased by 10.0% in the last 30 days, and increased by 212.6% in the last year.

Curiox Biosystems has an EPS (earnings per share) of $-1.05.

See more trading valuation data for Curiox Biosystems
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$1B-2.9%-10.0%-23.8%212.6%$-1.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Curiox Biosystems Valuation Multiples

Curiox Biosystems trades at 305.1x EV/Revenue multiple, and (67.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Curiox Biosystems

EV / Revenue (LTM)


Curiox Biosystems Financial Valuation Multiples

As of May 16, 2026, Curiox Biosystems has market cap of $1B and EV of $1B.

Curiox Biosystems has a P/E ratio of (58.9x).

LTMLast FY202320242025202620272028
EV/Revenuen/mn/m230.1xn/mn/m
EV/EBITDA(67.1x)(189.7x)n/m(67.1x)
EV/EBIT(129.0x)(129.0x)(147.9x)(116.7x)(127.0x)
EV/Gross Profitn/mn/mn/mn/m
P/E(58.9x)(58.9x)(157.1x)(195.0x)(58.0x)
EV/FCF(138.9x)(186.5x)(156.9x)(138.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Curiox Biosystems Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Curiox Biosystems Margins & Growth Rates

In the most recent fiscal year, Curiox Biosystems reported gross margin of 41%, EBITDA margin of (452%), and net margin of (520%).

See estimated margins and future growth rates for Curiox Biosystems

Curiox Biosystems Margins

Last FY20242025202720282029
Gross Margin41%56%41%
EBITDA Margin(452%)(103%)(452%)
EBIT Margin(235%)(292%)(239%)
Net Margin(520%)(176%)(528%)
FCF Margin(218%)(217%)(218%)

Curiox Biosystems Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(32%)12%
Gross Profit Growth(33%)(17%)
EBITDA Growth(43%)393%
EBIT Growth27%(8%)
Net Profit Growth(19%)236%
FCF Growth19%13%

Data powered by FactSet, Inc. and Morningstar, Inc.

Curiox Biosystems Operational KPIs

Access forward-looking KPIs for Curiox Biosystems
Last FY202320242025202620272028
S&M Expenses to Revenue22%28%34%22%
G&A Expenses to Revenue34%18%36%34%
R&D Expenses to Revenue51%31%55%51%
Opex to Revenue280%212%347%280%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Curiox Biosystems Competitors

Curiox Biosystems competitors include Conmed, Mani Inc., Kuros Biosciences, Integra Lifesciences, iRadimed, Artivion, Butterfly Network, Shanghai Haohai, Xvivo Perfusion and Inspire Medical Systems.

Most Curiox Biosystems public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Conmed1.4x1.4x6.9x6.9x
Mani Inc.4.6x4.3x12.8x11.9x
Kuros Biosciences5.4x6.1x63.1x52.1x
Integra Lifesciences1.8x1.7x9.1x8.9x
iRadimed12.6x12.2x38.6x36.6x
Artivion3.0x2.9x14.6x14.1x
Butterfly Network9.1x8.4x(33.3x)(35.1x)
Shanghai Haohai2.3x2.2x11.9x11.0x

This data is available for Pro users. Sign up to see all Curiox Biosystems competitors and their valuation data.

Start Free Trial

Curiox Biosystems Funding History

Before going public, Curiox Biosystems raised $30M in total equity funding, across 2 rounds.


Curiox Biosystems Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Mar-22Series CKB Investment; Luha Private Equity; QUAD Investment Management$15MCuriox Biosystems, based in Woburn, Mass., develops Laminar Wash technology, which automates biological sample preparation to enable efficient, standardized workflows for life science research and product development. The company closed a $15 million Series C funding round on March 16, 2022, led by Luha Private Equity with participation from KB Investment Co. and Quad Investment Management Corp. The funds aim to expand global operations, reinforce commercial and production capacity, and launch new cell preparation products. Curiox plans to mass-produce over 1,000 cell washing systems annually within three years to support a goal of doubling sales yearly. Laminar Wash has driven sales growth of 168% since 2019, positioning Curiox as a first mover in cell sample prep automation, with CEO Kim estimating the global market at $5B.
Oct-19Series BDayli Partners; HB Investment; IMM Investment; KB Investment; Muirwoods Ventures; QUAD Investment Management; SV Investment Partners$15MCuriox Biosystems, a Singapore-based A*STAR spinoff developing bioinstrumentation solutions for cell analysis and therapy in pharmaceutical and biotech industries, raised US$15 million in a Series B funding round on October 16, 2019. The round was backed by Korean investors including KB Investment, IMM Investment, QUAD Investment, HB Investment, DAYLI Investment, Muirwoods Ventures, and SV Investment Partners, with support from cornerstone investor ZIG Ventures. The funds were intended to scale up and accelerate global commercialization activities, following successful market penetration in the USA, PRC, Korea, and Europe. Curiox commercializes Laminar Wash technology, which standardizes cell sample preparation workflows for life science research and product development. The company planned to pursue an IPO on the Korean stock exchange KOSDAQ within 36 months of the round. Later traction included 168% sales growth since 2019, noted in connection with a subsequent 2022 Series C round.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Curiox Biosystems

When was Curiox Biosystems founded?Curiox Biosystems was founded in 2018.
Where is Curiox Biosystems headquartered?Curiox Biosystems is headquartered in South Korea.
Is Curiox Biosystems publicly listed?Yes, Curiox Biosystems is a public company listed on Korea Exchange.
What is the stock symbol of Curiox Biosystems?Curiox Biosystems trades under 445680 ticker.
When did Curiox Biosystems go public?Curiox Biosystems went public in 2023.
Who are competitors of Curiox Biosystems?Curiox Biosystems main competitors include Conmed, Mani Inc., Kuros Biosciences, Integra Lifesciences, iRadimed, Artivion, Butterfly Network, Shanghai Haohai, Xvivo Perfusion, Inspire Medical Systems.
What is the current market cap of Curiox Biosystems?Curiox Biosystems' current market cap is $1B.
What is the current revenue of Curiox Biosystems?Curiox Biosystems' last 12 months revenue is $3M.
What is the current EV/Revenue multiple of Curiox Biosystems?Current revenue multiple of Curiox Biosystems is 305.1x.
Is Curiox Biosystems profitable?No, Curiox Biosystems is not profitable.
What is the current net income of Curiox Biosystems?Curiox Biosystems' last 12 months net income is ($18M).
How many companies Curiox Biosystems has acquired to date?Curiox Biosystems hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Curiox Biosystems has invested to date?Curiox Biosystems hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Curiox Biosystems

Lists including Curiox Biosystems

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial